Ketamine Tolerated Dose for Postpartum Depression and Pain After Cesarean Delivery (PREPARE 1)
Key facts
- Who runs it
- Grace Lim, MD, MS
- Where
- Pittsburgh, United StatesSee the site
- Trial code
- Status
- Completed
- Phase
- Phase 1
- People taking part
- 12 people enrolled
- Started
- 25 Sept 2023
- Ended
- 19 Sept 2024
- Type of study
- Interventional, 4 groups
- Treatments tested
- Ketamine (Ketalar) Dose Level 1
- Ketamine (Ketalar) Dose Level 2
- Ketamine (Ketalar) Dose Level 3
- Ketamine (Ketalar) Dose Level 4
- Record updated
- 12 September 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women only
- Healthy volunteers
- Can take part
Show the full registry criteria (17)Hide the full registry criteria
Who can take part
- Adults 18 years and older
- Cesarean Delivery
- American Society of Anesthesiologists Physical Status of 2 or 3
- Neuraxial anesthesia with neuraxial morphine
- Term delivery ≥37 weeks gestation
- Either planning not to breastfeed, OR receiving ketamine as part of routine clinical care
Who cannot take part
- Allergy to study medications
- Hypertensive disorder of pregnancy
- Medical History exclusions: ketamine or PCP (phencyclidine) abuse, schizophrenia or psychosis, liver or renal insufficiency, uncontrolled hypertension, chest pain, arrhythmia, head trauma, or intracranial hypertension, uncontrolled thyroid disease, or other contraindications to ketamine
- General anesthesia
- ASA PS 4 or higher
- Contraindications to neuraxial anesthesia
- Preterm delivery (<37 weeks gestation)
- Anticipated fetal-neonatal complex care plan
- Participating in another pain intervention trial
- Pre-eclampsia with severe features
- Hemodynamic instability
Where in United States
- Magee-Womens Hospital of UPMCPittsburgh, United States
About the trial
What the trial wants to find out
The purpose of this study is to identify a tolerable dose for postpartum ketamine infusion using a maximum tolerated dose (MTD) 3+3 design. A loading dose over 1 hour will be the MTD variable to be tested, as our data suggest that ketamine side effects occur with the loading dose. The investigators hypothesize that subanesthetic ketamine dose will be well tolerated and any noted side effects will be rated acceptable by postpartum women following cesarean delivery.
The 4 groups in the trial
- Ketamine (Ketalar) Dose Level 1Treatment being tested
Ketamine (Ketalar) Dose Level 1: Loading Dose: 0.05 mg/kg/hr X 1 hour; Maintenance Dose 0.05 mg/kg/hr x 12 hours
- Ketamine (Ketalar) Dose Level 2Treatment being tested
Ketamine (Ketalar) Dose Level 2: Loading Dose: 0.08 mg/kg/hr X 1 hour; Maintenance Dose 0.05 mg/kg/hr x 12 hours
- Ketamine (Ketalar) Dose Level 3Treatment being tested
Ketamine (Ketalar) Dose Level 3: Loading Dose: 0.12 mg/kg/hr X 1 hour; Maintenance Dose 0.05 mg/kg/hr x 12 hours
- Ketamine (Ketalar) Dose Level 4Treatment being tested
Ketamine (Ketalar) Dose Level 4: Loading Dose: 0.18 mg/kg/hr X 1 hour; Maintenance Dose 0.05 mg/kg/hr x 12 hours
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Ketamine Tolerated Dose for Postpartum Depression and Pain After Cesarean Delivery (PREPARE1)
- Record updated
- 12 September 2025